Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
06/2014
06/17/2014US8754034 Structure-based design of peptide inhibitors of amyloid fibrillation
06/17/2014US8754033 Peptides for inhibiting transglutaminase
06/17/2014US8754031 Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
06/17/2014US8754030 Defensin-antigen fusion proteins
06/17/2014US8753864 Recombinant N-glycosylated proteins from procaryotic cells
06/17/2014US8753837 Designer Oxyphotobacteria and greenhouse distillation for photobiological ethanol production from carbon dioxide and water
06/17/2014US8753822 Neoepitope detection of disease using protein arrays
06/17/2014US8753698 Anti-hypertensive functional food products
06/17/2014US8753697 Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
06/17/2014US8753690 Methods and compositions for delivering interleukin-1 receptor antagonist
06/17/2014US8753671 Filament based on hyaluronic acid in the form of free acid and method for obtaining it
06/17/2014US8753670 Fibrin foam and process
06/17/2014US8753650 Staphylococcus aureus proteins and nucleic acids
06/17/2014US8753644 Grass peptides for vaccine
06/17/2014US8753641 Combination of intercalating organometallic complexes and tumor seeking biomolecules for DNA cleavage and radiotherapy
06/17/2014US8753640 MIC-binding antibodies and methods of use thereof
06/17/2014US8753633 Human antibodies that bind human TNFα
06/17/2014US8753607 Methods and kits for the differential diagnosis of Alzheimer's disease versus frontotemporal dementia and for the diagnosis of frontotemporal dementia, comprising FAS-L and CK 18 as biomarkers
06/17/2014US8753605 Imaging probes, methods of making imaging probes, and methods of imaging
06/17/2014CA2664795C Therapeutic compositions to improve the effect of the therapy with anti-epidermal growth factor receptor antibodies
06/17/2014CA2641588C Stabilized compositions of proteins having a free thiol moiety
06/17/2014CA2616525C Novel biologically active peptides and their new uses
06/17/2014CA2584806C Treatment of obesity and related disorders
06/17/2014CA2546665C Protein from horn fly saliva that disrupts hemostasis
06/17/2014CA2533479C Peptide protein translation inhibitor and the use thereof for protein translation control
06/17/2014CA2472937C Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
06/17/2014CA2370306C Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
06/17/2014CA2366062C Human dickkopf-related protein and nucleic acid molecules and uses therefor
06/17/2014CA1341638C Fibroblast growth factor
06/12/2014WO2014089526A1 Treatment for chronic kidney disease
06/12/2014WO2014089507A1 Fgf-10 complexes
06/12/2014WO2014089493A1 Antibodies against factor xii and uses thereof
06/12/2014WO2014089487A1 Methods and compositions for intrathecally administered treatment of mucupolysaccharidosis type iiia
06/12/2014WO2014089354A1 Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
06/12/2014WO2014089267A1 Galectin-3 fusion proteins
06/12/2014WO2014089177A2 Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
06/12/2014WO2014089146A1 Compositions and methods for in vivo delivery of antisense compounds
06/12/2014WO2014089100A2 Systems and methods for encoding and decoding of check-irregular non-systematic ira codes
06/12/2014WO2014089088A1 Peptide compounds and methods of production and use thereof
06/12/2014WO2014089022A1 Method for diagnosing and treating kidney injury or disease
06/12/2014WO2014089013A1 Use of trpv4 antagonists to ameliorate hydrocephalus and related materials and methods
06/12/2014WO2014089009A1 Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses
06/12/2014WO2014088836A1 O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
06/12/2014WO2014088623A1 Linaclotide compositions
06/12/2014WO2014088292A1 Pharmaceutical composition comprising inhibitor of expression or activation of carbonyl reductase 1 protein for preventing or treating colorectal cancer or inhibiting metastasis of same
06/12/2014WO2014087904A1 Agent for preventing or treating osteoclast-induced disease
06/12/2014WO2014087394A1 Thrombin solution and methods of use thereof
06/12/2014WO2014087218A1 Gm-csf for use in the prevention of spontaneous abortion and embryo implantation failure
06/12/2014WO2014087037A1 Use of the growth factor derived from platelets or a selective agonist of the at2 receptor for the treatment of vascular calcifications
06/12/2014WO2014087022A1 Protein slurp-1 for use in the treatment of ocular diseases
06/12/2014WO2014086994A1 Hsp for use in treatment for imiquimod related side effects
06/12/2014WO2014086785A1 Compounds useful in the treatent and/or care of the skin, hair and/or mucous membranes and their cosmetic or pharmaceutical compositions
06/12/2014WO2014086364A1 Positron emitting radionuclide labeled peptides for human upar pet imaging
06/12/2014WO2014086258A1 Use of yam glycoprotein for improving activity of mitochondrial oxidative metabolic enzyme of brain cell
06/12/2014WO2014086257A1 Use of yam glycoprotein for preparing drugs for treating nephritis and renal hypertension
06/12/2014WO2014086255A1 Use of composition of yam polysaccharides and yam proteins
06/12/2014WO2014085861A1 A method of purifying therapeutic proteins
06/12/2014WO2014071339A3 Bremelanotide therapy for female sexual dysfunction
06/12/2014WO2014066419A3 Methods for reducing risks associated with heart failure and factors associated therewith
06/12/2014WO2014064652A3 Stable pharmaceutical composition of peginterferon alpha-2b
06/12/2014WO2014062870A3 Treatment of brain injury or trauma with tsg-6 protein
06/12/2014WO2014057484A8 Peptides for the treatment of neurodegenerative diseases
06/12/2014WO2013151596A3 System and method of losing weight
06/12/2014US20140165226 Antimicrobial Agents from Microbial Genomes
06/12/2014US20140165223 Tnf superfamily trimerization inhibitors
06/12/2014US20140163451 Methods and Compositions for Treating Conditions of the Eye
06/12/2014US20140163231 Hepatitis C Virus Inhibitors
06/12/2014US20140163051 Use and Application of a Pharmaceutical Composition Containing a Mixture of Natural-Origin Heterocyclical Guanidine, For Cosmetology, Wound Healing, Focal Dystonia and Muscular Spasm- Related Clinical Pathologies
06/12/2014US20140162963 Treatment of Constipation-Predominant Irritable Bowel Syndrome
06/12/2014US20140162962 Novel lipids and compositions for intracellular delivery of biologically active compounds
06/12/2014US20140162960 Scaffold-Kinase Interaction Blockades and Uses Thereof in Treating Cancer
06/12/2014US20140162959 Suspension type topical formulations comprising cyclic depdipeptide
06/12/2014US20140162958 Copolymer-1 Composition and Methods of Use
06/12/2014US20140162957 Lyophilized formulation of tat-nr2b9c
06/12/2014US20140162955 Antagonizing Heparin With Salicylamide Compounds And Histamine Blocking Agents
06/12/2014US20140162954 Fusion of human growth hormone and albumin formulation and uses thereof
06/12/2014US20140162953 Use of inhalable powder formulation comprising growth hormone for preventing or treating nmda receptor hypofunction-related diseases
06/12/2014US20140162952 Erap1-derived peptide and use thereof
06/12/2014US20140162950 Method for inhibiting peritoneal metastasis caused by gastric cancer cells
06/12/2014US20140162948 Formulation for increasing bioavailability of neurturin
06/12/2014US20140162946 Formulations and methods for weight loss and body contouring
06/12/2014US20140162944 Controlled release peptide formulations
06/12/2014US20140162942 Inhibition of cyp3a drug metabolism
06/12/2014US20140162937 Polymyxin derivatives and uses thereof
06/12/2014US20140162935 Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug
06/12/2014US20140162934 Novel lipids and compositions for intracellular delivery of biologically active compounds
06/12/2014US20140162358 Endogenous and Non-Endogenous Versions of Human G Protein-Coupled Receptors
06/12/2014US20140161900 Compositions for Regenerating Defective or Absent Myocardium
06/12/2014US20140161896 Particles for the treatment of neurodegenerative diseases
06/12/2014US20140161887 Adjuvant compositions
06/12/2014US20140161859 Dermal micro-organs, methods and apparatuses for producing and using the same
06/12/2014US20140161816 Anti- tnf antibodies, compositions, methods and uses
06/12/2014US20140161805 Methods for Manipulating Phagocytosis Mediated by CD47
06/12/2014US20140161797 Injectable Non-Aqueous Suspension
06/12/2014US20140161789 Therapeutic vegetable substances
06/12/2014US20140161787 Pharmaceutical Preparation for the Treatment of the Symptoms of Addiction and Method of Diagnosing Same
06/12/2014US20140161786 Therapeutic compositions and related methods
06/12/2014US20140161784 Compositions and methods for enhancing recovery after surgery or an athletic performance
06/12/2014US20140161783 Pharmaceutical Liquid Composition of Botulinum Toxin With Improved Stability
06/12/2014US20140161773 Use of an agent that restores tissue perfusion and oxygenation
1 ... 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 ... 3163